Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4936619 | 0.97 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL1308918 | 0.97 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL12932939 | 0.91 | CXCR4 (0.50) | SIGMAR1ALDH1A1HTTCXCR4CHRM5 | |
| SCHEMBL25096239 | 0.89 | CXCR4 (0.44) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL24122600 | 0.87 | CXCR4 (0.57) | SIGMAR1ALDH1A1HTTSMN1; SMN2CXCR4 | |
| SCHEMBL19021173 | 0.85 | SIGMAR1 (0.38) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| Trifluoroacetic Acid SCHEMBL5269618 | 0.82 | SIGMAR1 (0.45) | SIGMAR1ALDH1A1HTTSMN1; SMN2CHRM5 | |
| SCHEMBL21472825 | 0.82 | ACHE (0.39) | SIGMAR1ALDH1A1HTTCHRM5ADRA2C | |
| SCHEMBL14584234 | 0.82 | SIGMAR1 (0.39) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL3919857 | 0.80 | SIGMAR1 (0.38) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU SALUSTIER BIOSCIENCES CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-6316618-B1 | REACTING ETHYL 2-(4-CHLORO-5-FLUORO-2-HALO-3-NITOBENZOYL)-3-((1-HYDROXYPROPY-2(S) -YL)AMINO)ACRYLATE IN PRESENCE OF BASE, REACTING WITH PIPERIDINE COMPOUND, HYDROLYSIS, CYCLIZATION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2001-11-13 | — | — | US | disclosed |
| EP-1073662-A1 | PROCESS FOR PREPARING (-)PYRIDOBENZOXAZINE CARBOXYLIC ACID DERIVATIVES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000050428-A1 | PROCESS FOR PREPARING (-)PYRIDOBENZOXAZINE CARBOXYLIC ACID DERIVATIVES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2000-08-31 | — | — | WO | disclosed |
| US-5180718-A | Antilipemic Agents | CIBA-GEIGY CORPORATION (US) | 1993-01-19 | — | — | US | disclosed |
| EP-0475895-A1 | Acyl derivatives of rifamycins and their use as medicaments | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| EP-0434621-A2 | Rifamycin derivatives and processes for the manufacture thereof | CIBA-GEIGY AG (CH) | 1991-06-26 | — | — | EP | disclosed |
| US-4353826-A | ANTITUBERCULAR ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1982-10-12 | — | — | US | disclosed |
| US-4261891-A | BACTERICIDES, ANTITUBERCULAR AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| US-4213984-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-22 | — | — | US | disclosed |
| US-4005077-A | DERIVATIVES OF RIFAMYCIN S OR SV | CIBA-GEIGY CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | SIGMAR1 2433/4885ALDH1A1 2338/4885HTT 2071/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | SIGMAR1 158/4885ALDH1A1 2758/4885HTT 4284/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | SIGMAR1 3665/4885ALDH1A1 649/4885HTT 1765/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | SIGMAR1 3038/4885ALDH1A1 4021/4885HTT 298/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | SIGMAR1 4229/4885ALDH1A1 2264/4885HTT 3760/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | SIGMAR1 4514/4885ALDH1A1 4659/4885HTT 933/4885 |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | FLT3, ABL1, MCL1 | SIGMAR1 3388/4885ALDH1A1 3264/4885HTT 3620/4885 |
| US-20230348487-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | JAK3, JAK2, JAK1 | SIGMAR1 2903/4885ALDH1A1 2774/4885HTT 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.